SGMO Rentabilitas operasi Sangamo Therapeutics Inc.

SGMO (Sangamo Therapeutics Inc.) - tandha merek perusahaan

Sangamo Therapeutics (SGMO) is scaling its business through the licensing of DNA designs, receiving upfront payments from industry behemoths. Patent superiority in gene editing provides the company with pricing power. The anticipation of clinical results and partner payments defines current prospects. The -273.10 mark reflects fresh data, which is visualized by the operating profit margin trend.

SGMO: Rentabilitas dodolan operasi Sangamo Therapeutics Inc. 04.07.2022 - 09.05.2026

Rincian metrik keuangan lan pasar Sangamo Therapeutics (SGMO)

- statistik dhuwit lan arus kas:
Analisis wiwitan perusahaan:Sangamo BioSciences, SGMO
Produk merek Sangamo BioSciences

Sangamo Therapeutics (SGMO) minimizes shortage risks and maintains cost stability through the diversification of its bio-raw material suppliers. The operating margin trend illustrates the efficiency of managing these expenses relative to revenue. This metric measures the share of core business profit before interest and taxes, revealing the actual profitability of operations. Daily monitoring eliminates the uncertainty of quarterly reports by identifying hidden fluctuations in yield. This tool allows for an objective assessment of the asset's business model sustainability.

Analisis perusahaan pesaing

Margin dodolan operasi TEM|QGEN - Tingkat bathi adhedhasar bathi operasi|Margin operasi IONS|RGEN - Rentabilitas dodolan operasi|Rentabilitas operasi Avidity RNA|Margin operasi CRISPR Therapeutics Corp CRSP|GeneDx Corp - Margin operasi|Ultragenyx Pharma (RARE) - Margin dodolan operasi|beamtx.com (BEAM) - Rentabilitas operasi|SRPT: Rasio bathi operasi|Margin dodolan operasi TWST|TXG - Tingkat bathi adhedhasar bathi operasi|Margin operasi NTLA|Rentabilitas kegiatan operasi Stoke Therapeutics|Rentabilitas operasi BioLife Solutions BLFS|Wave Life Sciences (WVE) - Rentabilitas dodolan operasi|Maze Therapeutics, Inc. - Margin operasi|Rentabilitas kegiatan operasi Sionna Therapeutics, Inc. SION|Prime Medicine Bio (PRME) - Rentabilitas operasi|TSHA: Rasio bathi operasi|Rentabilitas operasi uniQure Pharma|MGTX - Tingkat bathi adhedhasar bathi operasi|Margin operasi RGNX|Rentabilitas operasi SLDB (Solid Biosciences)|Ocugen Corp - Margin dodolan operasi|PACB: Rentabilitas dodolan miturut bathi operasi|benitec.com - Margin operasi|DSGN - Margin operasi|RCKT: Margin operasi|FDMT (4D Molecular Therapeutics Inc) - Rentabilitas operasi|Margin dodolan operasi LXEO|Rentabilitas operasi KRRO|Margin operasi EDIT|SLN - Rentabilitas dodolan operasi|Margin operasi PRQR (ProQR)|CDXS - Margin dodolan operasi|Nautilus Biotechnology - Margin operasi|Tingkat bathi operasi MGX (Metagenomi, Inc)|DTIL: Margin operasi|GBIO: Rasio bathi operasi|Rentabilitas operasi Boundless Bio Inc.|Margin dodolan operasi Exicure (XCUR)|Margin operasi IMNN|PHIO (Phio Pharmaceuticals Corp.) - Tingkat bathi operasi|Mustang Bio, Inc. - Margin dodolan operasi|RNAZ - Margin dodolan operasi|BNGO: Margin dodolan operasi|APDN (Applied DNA Sciences Inc) - Rentabilitas dodolan miturut bathi operasi|BLUE (Bluebird Bio) - Margin dodolan operasi|ImmunoPrecise Antibodies Ltd - Tingkat bathi operasi|OMGA (Omega Therapeutics Inc) - Margin operasi|Rentabilitas operasi OMIC|Rentabilitas operasi Regulus Therapeutics Inc. (RGLS)|Margin dodolan operasi Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Margin dodolan operasi|Tingkat bathi operasi TCON|UBX - Rentabilitas operasi